原文出处:KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemo...
(生物谷Bioon.com) 原文出处:KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer 版权声明 本网站所有注明“...
Marth C, Moore RG, Bidzinski M, et al. Lenvatinib Plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: primary results of the phase 3 ENGOT-En9/LEAP-001 study. Presented at: Society of Gynecologic Oncology 2024 Annual Meeting for Women’s ...
文章标题为:Lenvatinib and pembrolizumab in patients with advanced endometrial cancer。 基于该研究数据,美国FDA在2019年9月中旬已加速批准Keytruda+Lenvima联合治疗方案,用于治疗既往接受系统治疗后病情进展、不适合根治性手术或放射治疗、不是微卫星不稳定性高(MSI-H)或错配修复缺陷(dMMR)的晚期子宫内膜癌患者。此外...
[2] Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. Retrieved January 19, 2022, from https://www.nejm.org/doi/full/10.1056/NEJMoa2108330 (原文有删减)
文章标题为:Lenvatinib and pembrolizumab in patients with advanced endometrial cancer。 基于该研究数据,美国FDA在2019年9月中旬已加速批准Keytruda+Lenvima联合治疗方案,用于治疗既往接受系统治疗后病情进展、不适合根治性手术或放射治疗、不是微卫星不稳定性高(MSI-H)或错配修复缺陷(dMMR)的晚期子宫内膜癌...
LENVIMA, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR), as determined by an FDA-approved test, or not microsatellite instability-high (MSI-H), who have disease progression following pri...
Health care professionals may find information about KEYTRUDA® (pembrolizumab) and LENVIMA® (lenvatinib).
Pembrolizumab (Keytruda) is approved by the FDA to be used in combination with lenvatinib (Lenvima) for the treatment of certain patients with advanced endometrial cancer that is not MMR deficient (dMMR) or MSI high (MSI-H) after at least one other drug treatment has been tried.Continue read...
Endometrial carcinoma (EC) in combination with pembrolizumab for the treatment of patients with advanced EC that is not microsatellite instability-high or mismatch repair deficient, who have disease progression following prior systemic therapy, and are not candidates for curative surgery or radiation. ...